Clinical Trial Update: Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports a combination of tazemetostat with zanubrutinib and an anti-CD20 monoclonal antibody for relapsed or refractory B-cell non-Hod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Anti-CD20 monoclonal antibody
• BRUKINSA (ZANUBRUTINIB)
• TAZVERIK (TAZEMETOSTAT)

Snippet

Sponsor: University of Utah | Conditions: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Status: SUSPENDED